Staidson Stock Hits Day Low of CNY 24.01 Amid Price Pressure

Staidson (Beijing) Biopharmaceuticals Co., Ltd. experienced a significant decline today, with the stock dropping by 11.49% on July 17, 2026. The stock reached an intraday low of CNY 24.01, reflecting ongoing challenges within the company. Over the past year, Staidson has faced considerable difficulties, with a staggering 45.07% decrease in stock value, contrasting sharply with the China Shanghai Composite's positive performance of 7.03%. The company's financial metrics reveal a concerning trend, including a negative net worth and a return on equity of -11.48%. Additionally, net sales have declined at an annual rate of 15.81%, while operating profit has shown minimal growth of 8.53% over the last five years. Despite a notable 142.81% increase over the past three years, the recent performance indicates a troubling trajectory. Staidson's market capitalization stands at CNY 11,063 million, categorizing it as a large-cap company within the pharmaceuticals and biotechnology sector. The stock's current trading conditions suggest heightened risk, as it continues to underperform relative to broader market trends.